List view / Grid view
In the arsenal of approved small molecule drugs, effective, genetically-targeted therapies for the treatment of autoimmune diseases are conspicuously scarce. ImmunoMolecular Therapeutics (IM Therapeutics) has developed a paradigm for the discovery and development of new molecular entities as a broad platform for blocking genetic targets that confer risk of disease development…
Featured in this in-depth focus, articles exploring why cleanroom infrastructure must transform to meet the needs of the cell and gene therapy industry and discussing a novel platform for discovering and developing genetically-targeted therapies for autoimmune diseases.
We offer high quality analytical testing solutions for pharmaceutical and biopharmaceutical products through all phases of drug development, from discovery through early development and commercialisation. Find out more in this guide…
BioVersys will receive €20 million in funding to support its development of new treatments for antimicrobial resistant infections.
Mass spectrometry has numerous applications in pharmaceutical research, from initial discovery through to characterisation and quality control. In this article, Dr Ioannis Papayannopoulos details the role of mass spectrometry in pharma R&D by highlighting established and novel applications of the technique in drug discovery and development.
GEA’s digitally-enabled process optimisation tools improve the customer experience and expedite the successful completion of pharmaceutical research, development and production projects. This comprehensive suite of process simulations, digital twins, augmented/virtual reality systems and remote support solutions represents a safe and effective environment in which to achieve operational excellence, expedite FATs,…
![Phone screen displaying PerkinElmer logo next to a laptop keyboard [Credit: rafapress / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/PerkinElmer-3-300x278.jpg)
![Phone screen displaying PerkinElmer logo next to a laptop keyboard [Credit: rafapress / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/PerkinElmer-3-scaled-e1604320818816.jpg)
PerkinElmer will expand its automated life sciences discovery and applied genomics solutions with the acquisition.
In this article Pramod Kumar, a Senior Research Analyst (Healthcare) at P&S Intelligence, explores how single-cell analysis techniques are used for both pharmaceutical R&D and clinical, diagnostic applications.
The fund has already raised $1 billion to support clinical research of novel antibiotics and intends to bring up to four new antibiotics to market by 2030.
The NHS is offering two contracts to pay pharma companies at the start of their research into antibiotics, to promote the development of new antimicrobials.
The US FDA approved Phexxi™ (lactic acid, citric acid and potassium bitartrate) gel, the first non-hormonal, vaginal pH regulator contraceptive.
A group of four CROs at BioCity Nottingham have joined forces to collectively work on the research of COVID-19 therapies.
Heidi West discusses how academia, government and the pharmaceutical industry can work together to potentially repurpose drugs for the treatment of COVID-19.
The UK MRC and LifeArc are making £16 million available as grants to fund the establishment of Gene Therapy Innovation Hubs to improve resources for researchers and manufacturers.
A polio vaccine designed to be incapable of evolving the ability to cause disease in humans has shown promise in a Phase I clinical trial.
